3Li PK, Ho KK, Szeto CC, et ai. Prognostic indicators of IgA ne- phropathy in the Chinese-clinical and pathological perspec- tives. Nephrol Dial Transplant, 2002,17 : 64-69.
4Zhou FD,Zhao MH,Zou WZ, et al. The changing spectrum of primary glomerular diseases within 15 years: A surveyof 3331 patients in a single Chinese centre. NephrolDial Transplant, 2009,24 : 870-876.
5Lv JC, Zhang H, Zhou Y, et al. Natural history of immunoglob- ulin A nephropathy and predictive factors of prognosis:A long- term follow up of 204 cases in China. Nephrology, 201)8, 13: 242-246.
6Tam LS, Li EK, Wong CK, et al. Safety and efficacy of lefluno- mide in the treatment of lupus nephritis refractory or intolerant to traditional irnrnunosuppressive therapy: an open label tria. Ann Rheum Dis, 2006 , 65 : 417-418.
7Daniel CC, Rosanna CP, H TC, et al. The Oxford classifieation of IgA nePhroPathy: Rationale, clinicopathol ogiealeorrela- tions, and elassifieation. Kidney Int, 2009,76 : 534-545.
8IanS. DR, H. Terence C, StePhan T, et al. The Oxford classi- fication of IgA nephropathy:Pathology definitions, correla- tions, and reprodueibility. Kidney Int, 2009,76 : 546-556.
9Lou T,Wang C, Chen Z, et al. Randomised controlled trial of leflunomide in the treatment of immunoglobul in Anephropath. Nephrolog(Carlton), 2006,11 : 113-116.
10Schena FP. Immunoglobulin a nephropathy with mild renal le- sions:A call in the forest for the physicians and nephrologists. Am J Med,2001,110:499-500.
